Table 3 Outcomes of patients receiving intravenous PMB
| Outcomes | n (%) |
|---|---|
| Bacteria eradication rate, n (%) | 66 (77.65) |
| Treatment duration, median (IQR) | 11 (9, 13) |
| Adverse events, n (%) | 16 (16) |
| Nephrotoxicity | 7 (7) |
| Neurotoxicity | 6 (6) |
| Skin hyperpigmentation | 3 (3) |
| Eosinophil increase | 7 (7) |
| ICU mortality, n (%) | 12 (12) |
| Hospital mortality, n (%) | 15 (15) |
| 28-day mortality, n (%) | 40 (40) |